Prolium Bioscience raised $50 million to advance therapies for systemic sclerosis (SSc), or scleroderma, a rare, chronic autoimmune disease characterized by vascular injury, immune system dysregulation, and progressive fibrosis affecting both the skin and vital internal organs, including the lungs, heart, and gastrointestinal tract.
City: New York
State: NY
Investment Amount(In Millions): $50